Phase 3 22 items
Trials, agents, guidance
- Agent Obicetrapib
- Trial Menarini European phase 3 (NCT07614958)
- Trial Obicetrapib CCTA imaging trial
- Trial TANDEM
- Trial DalCor genotype-defined trial (NCT05918861)
- Trial BROOKLYN
- Trial PREVAIL
- Trial BROADWAY
- Trial dal-GenE
- Trial ACCELERATE
- Trial REVEAL
- Trial dal-OUTCOMES
- Trial ILLUMINATE
Studies
- REALIZE phase 3 trial: anacetrapib cuts LDL-C by 39·7% versus placebo in familial hypercholesterolaemia over one year (Lancet 2015)
- Pooled phase 3 safety data on 2,880 patients show obicetrapib matches placebo for adverse events, with no blood pressure signal (Am J Prev Cardiol 2026)
- Phase 3 trial finds anacetrapib added to statins cuts LDL-C by 37% and more than doubles HDL-C, well tolerated over 24 weeks (Am J Cardiol 2017)
- The dal-ACUTE trial finds dalcetrapib raises HDL cholesterol by a third after acute coronary syndrome but boosts cholesterol efflux by only a tenth (Eur Heart J 2014)
- REMBRANDT trial design: 300 ASCVD patients to test whether obicetrapib plus ezetimibe shrinks coronary plaque on CT angiography (Am Heart J 2025)
- Rationale and design of BROADWAY and BROOKLYN: 2,886 participants randomised to test obicetrapib on top of maximally tolerated therapy (Am Heart J 2024)
